Schätzungsweise 7,1 Millionen Kinder in den USA (11,4% der 3- bis 17-Jährigen) haben eine formelle Diagnose einer Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) erhalten, während ein rasanter Anstieg bei Erwachsenen die ambulante Psychiatrie transformiert. Gleichzeitig führen staatliche Produktionsquoten und Engpässe in der pharmazeutischen Lieferkette zu jahrelangen Ausfällen bei zentralen Stimulanzien in 48 Bundesstaaten. Die folgenden Daten stammen von den Centers for Disease Control and Prevention (CDC), der FDA Drug Shortage Database, der DEA, dem IQVIA Institute und SAMHSA.
Das Verständnis dieser Versorgungslage steht im Dialog mit den Auslastungen universitärer campus mental health services, Indikatoren der student mental health und der Nutzung digitaler mental health apps.
TL;DR
- 11,4% der US-Kinder (7,1 Millionen) haben eine ADHS-Diagnose erhalten (CDC NSCH).
- 61,5% der betroffenen Kinder nehmen verschriebene Medikamente zur Symptomkontrolle (CDC).
- Stimulanzien-Rezepte für Erwachsene (20–39 Jahre) stiegen um 45,1% in fünf Jahren (IQVIA).
- 76% der öffentlichen Apotheken melden anhaltende Lieferengpässe bei Stimulanzien (ASHP).
- Diagnosen bei erwachsenen Frauen nahmen zwischen 2018 und 2025 um 84% zu (CDC / Epic Health Research).
- DEA-Produktionsquoten für Amphetamine deckeln die nationale Produktion bei ca. 45.000 kg Wirkstoff (DEA).
- Telemedizin-Plattformen stellten 2025 38,2% der Erstdiagnosen bei Erwachsenen (SAMHSA).
- Über 185 Milliarden Dollar jährlich betragen die volkswirtschaftlichen Gesamtkosten in den USA (J. of Clinical Psychiatry).
- Jungen sind zu 14,5% betroffen, verglichen mit 8,0% bei Mädchen im Schulalter (CDC).
- 53,6% der diagnostizierten Kinder erhalten Verhaltenstherapie oder pädagogische Förderung (CDC NSCH).
- Engpässe bei Lisdexamfetamin-Generika betrafen 62% der Apotheken nach Patentablauf (FDA).
- 18,4% der Erwachsenen mit ADHS berichten von beruflichen Einschränkungen durch unbehandelte Symptome (CHADD).
1. Prevalence and Diagnostic Trajectories
Die ADHS-Diagnoseraten in den Vereinigten Staaten sind über zwei Jahrzehnte hinweg stetig gestiegen, bedingt durch verfeinerte diagnostische Kriterien und ein breiteres Problembewusstsein in der Bevölkerung.
| Demographic Cohort | ADHD Prevalence Rate (%) | Estimated Patient Count | 10-Year Trajectory Trend |
|---|---|---|---|
| Children Aged 3-17 (Total) | 11.4% | 7.10 Million | +18.8% Relative Growth |
| Male Youth (Aged 3-17) | 14.5% | 4.62 Million | +12.4% Relative Growth |
| Female Youth (Aged 3-17) | 8.0% | 2.48 Million | +33.3% Relative Growth |
| Adolescents (Aged 12-17) | 13.2% | 3.41 Million | +14.8% Relative Growth |
| Adults Aged 18-44 | 5.4% | 5.65 Million | +74.2% Relative Growth |
| Adults Aged 45 and Older | 2.1% | 2.68 Million | +42.1% Relative Growth |
Source: CDC National Survey of Children’s Health (NSCH) and National Health Interview Survey.
2. Prescription Volumes and Treatment Modalities
Die medikamentöse Therapie bildet weiterhin den Grundpfeiler bei mittelschwerer bis schwerer Symptomatik, häufig kombiniert mit verhaltenstherapeutischen Maßnahmen im schulischen Umfeld.
| Therapeutic Treatment Category | Share of Diagnosed Patients | Annual Prescriptions Dispensed | Primary Formulation Type |
|---|---|---|---|
| Mixed Amphetamine Salts (Adderall / XR) | 38.2% | 29.4 Million Rx | Short & Long-Acting Stimulant |
| Lisdexamfetamine Dimesylate (Vyvanse) | 27.4% | 21.1 Million Rx | Prodrug Long-Acting Stimulant |
| Methylphenidate (Ritalin / Concerta) | 22.1% | 17.0 Million Rx | Short & Osmotic Release Stimulant |
| Non-Stimulants (Atomoxetine, Guanfacine, Clonidine) | 12.3% | 9.5 Million Rx | SNRI / Alpha-2 Agonists |
| Behavioral Counseling Alone (No Rx) | 18.2% | N/A (Non-Pharm) | Psychosocial Support |
| Combined Medication & Behavioral Therapy | 31.5% | N/A (Multi-Modal) | Integrated Care Standard |
Source: IQVIA National Prescription Audit and CDC treatment pattern analyses.
3. The National Stimulant Supply Shortage
Seit Ende 2022 führen Produktionsausfälle und gesetzliche Obergrenzen zu einer anhaltenden Verknappung, die Apotheken vor erhebliche Belieferungsprobleme stellt.
| Shortage Metric / Indicator | Value / Rate | Regulatory Context | Tracking Agency |
|---|---|---|---|
| Pharmacies Reporting Active Stimulant Stockouts | 76.4% | Independent & Health System Sites | ASHP Drug Shortage Survey |
| Average Prescription Refill Delay Time | 12.8 Days | From Normal 24h Processing | Patient Advocacy Surveys |
| Patients Forcibly Switched to Alternate Formulations | 42.1% | Due to Local Out-of-Stock Status | CHADD Patient Tracker |
| Manufacturers Operating at 100% DEA Quota Limit | 84.0% | Cannot Exceed Allocated Ceiling | DEA / FDA Joint Letters |
| Unused DEA Quotas Returned by Inactive Producers | 1.1B Doses (Historical) | Logistical Allocation Inefficiencies | Senate Finance Committee |
Source: FDA Drug Shortages Database and ASHP Clinical Bulletins.
4. Telehealth Expansion and Digital Diagnosis
Die Aussetzung von Präsenzpflichten nach dem Ryan Haight Act ermöglichte den schnellen Ausbau telepsychiatrischer Versorgungsangebote im gesamten Bundesgebiet.
| Telehealth Dimension | Metric Value | Comparative Pre-2020 Baseline | Data Source Authority |
|---|---|---|---|
| Adult ADHD Initial Consultations via Telehealth | 38.2% | < 2.0% Pre-Pandemic | SAMHSA Behavioral Tracker |
| Average Wait Time for Virtual Evaluation | 9.4 Days | 48.2 Days (In-Person Clinic) | Fair Health / KFF |
| Clinicians Continuing Remote Controlled Substance Rx | 64.2% | Subject to DEA Flexibilities | American Psychiatric Assoc. |
| Follow-up Compliance via Telehealth Modalities | 78.4% | 62.1% In-Person Benchmark | Journal of Medical Internet Res. |
| DEA Extensions of Remote Prescribing Flexibilities | Active through late 2026 | Rulemaking in Progress | Federal Register Announcements |
Source: KFF Telehealth Tracking Briefs and American Psychiatric Association clinician surveys.
5. Economic Burden, Workplace Impact, and Education Accommodations
Die ökonomischen Folgen von ADHS umfassen schulische Nachteilsausgleiche über 504-Pläne sowie Produktivitätseinbußen durch Beeinträchtigungen exekutiver Funktionen im Berufsleben.
| Socioeconomic Impact Metric | Estimated Annual Value | Context / Methodology | Research Authority |
|---|---|---|---|
| Total Annual US Economic Burden of ADHD | ”$185.2 Billion” | Direct Healthcare & Societal Loss | J. of Clinical Psychiatry |
| Annual Excess Direct Healthcare Cost per Patient | ”$3,120” | Adjusted for Matched Controls | Health Care Cost Institute |
| K-12 Students with ADHD on 504 / IEP Plans | 68.4% | Public Elementary & Secondary | Dept of Education OCR |
| Adults Reporting Workplace Burnout or Job Change | 34.2% | Attributed to Executive Dysfunction | ADDitude Workplace Survey |
| Untreated Adult Productivity Loss per Worker | ”$4,350 Annually” | Absenteeism & Presenteeism | WHO Health & Work Performance |
Source: Journal of Clinical Psychiatry Economic Analyses and US Department of Education OCR.
Summary: ADHD Diagnosis and Prescriptions by the Numbers
| Clinical & Pharmaceutical Indicator | Value / Metric | Source Authority |
|---|---|---|
| US Children Diagnosed with ADHD (Ages 3-17) | 7.10 Million (11.4%) | CDC NSCH |
| Diagnosed Children Receiving Prescription Medication | 61.5% (~4.37M) | CDC NSCH |
| Diagnosed Children Receiving Behavioral Therapy | 53.6% | CDC NSCH |
| Five-Year Growth in Adult Stimulant Prescriptions | +45.1% | IQVIA Institute |
| Pharmacies Experiencing Ongoing Stimulant Stockouts | 76.4% | ASHP |
| Adult Female ADHD Diagnosis Growth (2018-2025) | +84.0% | Epic Health / CDC |
| Male vs Female Diagnosis Ratio in Youth | 1.81 to 1 (14.5% vs 8.0%) | CDC NSCH |
| Total Annual Prescriptions for Mixed Amphetamine Salts | 29.4 Million Rx | IQVIA |
| Total Annual Prescriptions for Lisdexamfetamine | 21.1 Million Rx | IQVIA |
| Share of Adult ADHD Consultations via Telehealth | 38.2% | SAMHSA |
| Average Refill Delay During Active Supply Shortage | 12.8 Days | ASHP / Advocacy |
| Total Annual US Societal & Healthcare Cost | $185.2 Billion | J. Clinical Psych. |
| K-12 Diagnosed Students Receiving 504 / IEP Support | 68.4% | US Dept of Education |
| Excess Annual Healthcare Expenditure per Patient | $3,120 | HCCI Benchmarks |
| Adults Reporting Job Adjustments Due to Symptoms | 34.2% | CHADD Surveys |
| DEA Controlled Substance Quota Volume (Amphetamines) | ~45,000 kg API | DEA Federal Register |
Methodology and Sources
Surveillance estimates derived from epidemiologic registries compiled by the Centers for Disease Control and Prevention (CDC), drug tracking records from the FDA Drug Shortages Database, and commercial dispensing audits from the IQVIA Institute.
-
CDC National Survey of Children’s Health (NSCH): Diagnostic Prevalence and Treatment Interventions.
-
FDA Drug Shortages Database and American Society of Health-System Pharmacists (ASHP) Drug Shortage Bulletins.
-
Drug Enforcement Administration (DEA) Established Aggregate Production Quotas for Schedule II Controlled Substances.
-
IQVIA Institute for Human Data Science: National Prescription Audit and Medicines Use in the U.S.
-
Substance Abuse and Mental Health Services Administration (SAMHSA): National Survey on Drug Use and Health.
-
Journal of Clinical Psychiatry: The Societal and Economic Costs of ADHD in the United States.
-
Data watch: Survey-based childhood diagnosis estimates rely on parental recall and formal clinical confirmation, which can produce modest variances relative to claims-based electronic health record (EHR) studies. Telehealth prescription shares reflect evolving federal regulatory waivers under DEA temporary rules.
Last updated: September 7, 2026. Quarterly updates track ongoing regulatory revisions, pharmaceutical manufacturing releases, and CDC epidemiological reports.